Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2
40
about 7.8 years
18+
1 site in IL
What this study is about
This trial is testing a new treatment with four drugs (decitabine, selinexor, carboplatin, and paclitaxel) for ovarian cancer patients whose cancer has returned. The goal is to learn about the side effects and effectiveness of this combination therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Decitabine
- 3.Take Paclitaxel
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, decitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules), selinexor
injection, intravenous, oral (Oral Tablet)
Primary: 40 participants evaluated for safety with treatment-related adverse events and grading using CTCAE 4.3.
Secondary: 40 participants evaluated for tolerability with treatment-related adverse events and grading using CTCAE 4.3., 40 participants evaluated to determine the clinical efficacy of this novel regimen in both platinum sensitive and resistant recurrent disease as measured by response rates. Response rates (partial response [PR] and complete response [CR])
Oncology